{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:16:38Z","timestamp":1791566198255,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1201100"],"award-info":[{"award-number":["2021YFA1201100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377090"],"award-info":[{"award-number":["22377090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21977080"],"award-info":[{"award-number":["21977080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030092"],"award-info":[{"award-number":["82030092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271895"],"award-info":[{"award-number":["82271895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072752"],"award-info":[{"award-number":["82072752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jconrel.2025.01.050","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:18:34Z","timestamp":1738041514000},"page":"797-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38\/MAPK and MDR pathways for cancer chemo-immunotherapy"],"prefix":"10.1016","volume":"379","author":[{"given":"Xiao-Meng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.01.050_bb0005","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: the first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cbpa.2014.02.003","article-title":"Metal-based anticancer chemotherapeutic agents","volume":"19","author":"Muhammad","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0030","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/med.21360","article-title":"Recent advances in platinum(IV) complex-based delivery systems to improve platinum(II) anticancer therapy","volume":"35","author":"Han","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/ph14020133","article-title":"Monofunctional platinum(II) anticancer agents","volume":"14","author":"Jin","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0050","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1039\/D1DT03886A","article-title":"Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities","volume":"51","author":"Ravera","year":"2022","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2020.111353","article-title":"Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?","volume":"217","author":"Gibson","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0060","first-page":"175","article-title":"Targeted delivery of platinum-based anticancer complexes","volume":"17","author":"Butler","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0065","article-title":"Insertion of (bioactive) equatorial ligands into platinum(IV) complexes","volume":"13","author":"Kastner","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0070","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1039\/D2DT03662B","article-title":"Biotinylated Pt(IV) prodrugs with elevated lipophilicity and cytotoxicity","volume":"52","author":"Spector","year":"2023","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0075","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jpha.2023.11.002","article-title":"Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma","volume":"14","author":"Yin","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0085","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.2174\/1381612822666160923115828","article-title":"Polypharmacology in precision oncology: current applications and future prospects","volume":"22","author":"Antolin","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0090","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12929-015-0128-0","article-title":"Heme oxygenase-1: emerging target of cancer therapy","volume":"22","author":"Chau","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/antiox8100475","article-title":"Role of heme oxygenase as a modulator of heme-mediated pathways","volume":"8","author":"Duvigneau","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111703","article-title":"Heme oxygenase-2 (HO-2) as a therapeutic target: activators and inhibitors","volume":"183","author":"Intagliata","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0110","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.freeradbiomed.2011.07.025","article-title":"Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice","volume":"51","author":"Was","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0115","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1158\/1078-0432.CCR-04-2159","article-title":"Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment","volume":"11","author":"Berberat","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0120","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/14756366.2021.1928111","article-title":"Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU\/HO-1 hybrid): design and preliminary in vitro evaluation","volume":"36","author":"Salerno","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0125","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ejpb.2012.04.016","article-title":"HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: in vitro and in vivo anticancer effect","volume":"81","author":"Fang","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1476-4598-8-37","article-title":"Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo","volume":"8","author":"Nuhn","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0135","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3390\/ijms21061923","article-title":"New arylethanolimidazole derivatives as HO-1 inhibitors with cytotoxicity against MCF-7 breast cancer cells","volume":"21","author":"Ciaffaglione","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0140","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1172\/JCI38739","article-title":"Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients","volume":"119","author":"Andersen","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10495-016-1216-7","article-title":"Inhibition of heme oxygenase-1 enhances the chemosensitivity of laryngeal squamous cell cancer Hep-2 cells to cisplatin","volume":"21","author":"Lv","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/2326-6066.CIR-13-0150","article-title":"Tumoral immune suppression by macrophages expressing fibroblast activation protein-\u03b1 and heme oxygenase-1","volume":"2","author":"Arnold","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0155","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1084\/jem.192.7.1015","article-title":"Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis","volume":"192","author":"Brouard","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0160","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.20480","article-title":"Biliverdin therapy protects rat livers from ischemia and reperfusion injury","volume":"40","author":"Fondevila","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0165","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.yexcr.2013.05.015","article-title":"Biliverdin reductase\/bilirubin mediates the anti-apoptotic effect of hypoxia in pulmonary arterial smooth muscle cells through ERK1\/2 pathway","volume":"319","author":"Song","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0170","doi-asserted-by":"crossref","first-page":"18148","DOI":"10.1016\/S0021-9258(19)37165-0","article-title":"Ferritin: a cytoprotective antioxidant strategem of endothelium","volume":"267","author":"Balla","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0175","article-title":"Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages","volume":"5","author":"Alaluf","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0180","first-page":"121","article-title":"Tumoral immune suppression by macrophages expressing fibroblast activation protein-\u03b1 and heme oxygenase-1, cancer","volume":"2","author":"Arnold","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0185","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.181.3.1887","article-title":"Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis, Cynader","volume":"181","author":"Liu","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0190","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccell.2016.06.005","article-title":"Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity","volume":"30","author":"Di Biase","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0195","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nm0302-240","article-title":"Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice","volume":"8","author":"Lee","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0200","doi-asserted-by":"crossref","first-page":"21369","DOI":"10.1074\/jbc.M109.027433","article-title":"Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt","volume":"284","author":"Wegiel","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0205","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.phrs.2016.09.031","article-title":"Calycosin suppresses expression of pro-inflammatory cytokines via the activation of p62\/Nrf2-linked heme oxygenase 1 in rheumatoid arthritis synovial fibroblasts","volume":"113","author":"Su","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0210","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1091\/mbc.e08-10-1005","article-title":"Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants","volume":"20","author":"Weis","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0215","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.3748\/wjg.v20.i26.8572","article-title":"Zinc protoporphyrin IX enhances chemotherapeutic response of hepatoma cells to cisplatin","volume":"20","author":"Liu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.11644","article-title":"Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin","volume":"109","author":"Fang","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0225","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1158\/0008-5472.CAN-09-0419","article-title":"A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer","volume":"69","author":"Alaoui-Jamali","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","article-title":"Nanoparticle delivery of cancer drugs","volume":"63","author":"Wang","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0235","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0240","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/10717544.2020.1831106","article-title":"Recent advances in drug delivery systems for enhancing drug penetration into tumors","volume":"27","author":"He","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0245","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/17425247.2011.566552","article-title":"Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity","volume":"8","author":"Gubernator","year":"2011","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0250","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11095-012-0903-5","article-title":"Drug loading of polymeric micelles","volume":"30","author":"Miller","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0255","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.2147\/IJN.S264498","article-title":"Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications","volume":"15","author":"Zhang","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0260","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0265","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.msec.2019.01.066","article-title":"Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer","volume":"98","author":"Kalyane","year":"2019","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0275","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bsheal.2022.03.003","article-title":"Biosafety assessment of delivery systems for clinical nucleic acid therapeutics","volume":"4","author":"Li","year":"2022","journal-title":"Biosaf. Health."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0280","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1038\/s41467-019-11193-x","article-title":"Probing the impact of sulfur\/selenium\/carbon linkages on prodrug nanoassemblies for cancer therapy","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2024.215774","article-title":"Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs","volume":"508","author":"Zhou","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0290","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1021\/acsnano.3c06194","article-title":"A trisulfide bond containing biodegradable polymer delivering Pt(IV) prodrugs to deplete glutathione and donate H2S to boost chemotherapy and antitumor immunity","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0295","article-title":"Targeting DNA damage and repair machinery via delivering WEE1 inhibitor and platinum(IV) prodrugs to stimulate STING pathway for maximizing chemo-immunotherapy in bladder cancer","volume":"36","author":"Wang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0300","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.05.004","article-title":"Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance","volume":"347","author":"Muraoka","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0305","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2023.08.035","article-title":"Emerging platinum(IV) prodrug nanotherapeutics: a new epoch for platinum-based cancer therapy","volume":"361","author":"Zheng","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0310","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1021\/acs.jmedchem.2c01660","article-title":"Combination of DNA damage, autophagy, and ERK inhibition: novel evodiamine-inspired multi-action Pt(IV) prodrugs with high-efficiency and low-toxicity antitumor activity","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0315","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejmech.2017.08.070","article-title":"Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents","volume":"142","author":"Dichiara","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0320","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/jm2015099","article-title":"Alterman from the first selective non-peptide AT(2) receptor agonist to structurally related antagonists","volume":"55","author":"Murugaiah","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0325","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","article-title":"Endocytosis in cancer and cancer therapy","volume":"23","author":"Banushi","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0330","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41419-019-2081-4","article-title":"Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells","volume":"10","author":"Kleih","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2025.01.050_bb0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10120-020-01111-2","article-title":"Mitochondrial GRIM-19 deficiency facilitates gastric cancer metastasis through oncogenic ROS-NRF2-HO-1 axis via a NRF2-HO-1 loop","volume":"2","author":"Wang","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0340","doi-asserted-by":"crossref","first-page":"32116","DOI":"10.1074\/jbc.M110.131284","article-title":"Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein","volume":"285","author":"Choi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0345","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-016-0219-6","article-title":"Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer","volume":"23","author":"Cheng","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0350","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-07-2199","article-title":"Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9","volume":"7","author":"Lin","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0355","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1093\/nar\/gkm824","article-title":"p53-dependent stimulation of redox-related genes in the lymphoid organs of gamma-irradiated--mice identification of Haeme-oxygenase 1 as a direct p53 target gene","volume":"35","author":"Meiller","year":"2007","journal-title":"Acids. Res."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/ijms20010039","article-title":"A dual role of heme oxygenase-1 in cancer cells","volume":"20","author":"Chiang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0365","first-page":"1961","article-title":"Stimulated upregulation of HO-1 is associated with inadequate response of gastric and ovarian cancer cell lines to hyperthermia and cisplatin treatment","volume":"18","author":"Cesna","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2022.101821","article-title":"Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2\/HO-1 potentiates cisplatin responsiveness in OSCC cells","volume":"64","author":"Han","year":"2022","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0380","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0385","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.addr.2013.08.004","article-title":"Nanopreparations to overcome multidrug resistance in cancer","volume":"65","author":"Patel","year":"2013","journal-title":"Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0390","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/ijc.34270","article-title":"The immunosuppression pathway of tumor-associated macrophages is controlled by heme oxygenase-1 in glioblastoma patients","volume":"151","author":"Magri","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0395","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","article-title":"Functional states of myeloid cells in cancer","volume":"41","author":"van Vlerken-Ysla","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.01.050_bb0400","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejmech.2017.08.070","article-title":"Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents","volume":"142","author":"Dichiara","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.050_bb0405","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bsheal.2022.01.001","article-title":"Biosafety chemistry and biosafety materials: a new perspective to solve biosafety problems","volume":"4","author":"Yu","year":"2022","journal-title":"Biosaf. Health."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T12:51:53Z","timestamp":1751201513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925000616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":81,"alternative-id":["S0168365925000616"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.050","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38\/MAPK and MDR pathways for cancer chemo-immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}